Hero Background

What does Hope mean to you?

In the fight against Cancer, relapse is the shadow, TRACER is the light

The Stark Reality of Relapse

Relapse reveals a critical gap in cancer care. Current methods often miss early signs of recurrence, leaving patients with less time to act and fewer options to fight.

All Cancers

Relative recurrence rates

NSCLC after resection: recurrence-free survival (to 5 yrs)

RFS (%) by stage

Breast (ER+): after 5 yrs endocrine therapy

20-yr distant recurrence risk (%)

Prostate: biochemical recurrence after RP

Cumulative recurrence (%)

Ovarian (epithelial): recurrence ranges by FIGO stage

Patients with recurrence (%) within ~5 yrs

A New Dawn with TRACER

Targeted Relapse Assessment via Cellular Effector Response

At the intersection of despair and determination, TRACER emerges as a beacon of hope - A cell-based theranostic platform that detects and responds to cancer relapse in real time.

Imagine a system that tirelessly patrols the body, catching the earliest signs of recurrence and acting swiftly to slow its spread. That’s the promise of TRACER.

Detecting the Unseen

Engineered monocytes circulate throughout the body, utilizing a CD147-specific receptor to detect cancer cells at an early stage, triggering the production of GLuc and anti-CD147 scFv antibodies.

Tagging for Action

Anti-CD147 scFv antibodies bind to CD147 receptors on cancer cells, suppressing tumor progression and limiting metastatic potential.

Early Warning System

As GLuc is excreted through the kidneys, a dipstick-based detection system enables rapid, non-invasive monitoring of cancer relapse.

From detection to action – Reshaping cancer surveillance with TRACER.